Onkologie. 2019:13(1):19-23 | DOI: 10.36290/xon.2019.004

The role of radiotherapy in the treatment of young patients with breast carcinoma

Tereza Kohlová
Onkologická klinika 1. LF UK a Všeobecné fakultní nemocnice v Praze

Breast carcinoma is the most commonly diagnosed malignancy in women globally. Recently the number of women with the disease developing in young age has been increasing. In 2016 7,220 women were diagnosed with breast carcinoma, with 139 women under-35 and with 221 cases being reported in the 35–39 age groups. It is quite a small group – less than 2 % in under-35 age group, 5 % out of the total in under-40 age group. Carcinomas in these women are more aggressive, commonly accompanied by genetic mutation. Quite frequently the diagnosis is made during pregnancy or in the period of breastfeeding. The best medical outcomes occur when adopting the multidisciplinary approach, with radiotherapy being its integral part. This work was created as a response to new guidelines on breast carcinoma radiation therapy published by the American Society for Radiation Oncology (ASTRO) in spring 2018.

Keywords: breast cancer, radiotherapy, hypofractionation, complete pathologic response

Published: March 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kohlová T. The role of radiotherapy in the treatment of young patients with breast carcinoma. Onkologie. 2019;13(1):19-23. doi: 10.36290/xon.2019.004.
Download citation

References

  1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice, ISS 1802-8861, dostupný na http://www.svod.cz
  2. Pan HY, Haffty BG, Falit BP, et al. Supply and Demand for Radiation Oncology in the United States: Updated Projections for 2015 to 2025. Int J Radiat Oncol Biol Phys. 2016; 96(3): 493-500. Go to original source... Go to PubMed...
  3. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline, Int J Radiat Oncol Biol Phys. 2018; 8:3, 145-152.
  4. Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002; 94(15): 1143-1150. Go to original source... Go to PubMed...
  5. Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006; 7(6): 467-471. Go to original source... Go to PubMed...
  6. Yarnold J, Ashton A, Bliss J, et al. Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol. 2005; 75: 9-17. Go to original source... Go to PubMed...
  7. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008; 371(9618): 1098-1107. Go to original source... Go to PubMed...
  8. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362(6): 513-520. Go to original source... Go to PubMed...
  9. Shaitelman SF, Schlembach PJ, Arzu I, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015; 1(7): 931-941. Go to original source... Go to PubMed...
  10. van Tienhoven G, Mijnheer BJ, Bartelink H, et al. Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview. Strahlenther Onkol. 1997; 173(4): 201-207. Go to original source... Go to PubMed...
  11. de Bock GH, van der Hage JA, Putter H, et al. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer. 2006; 42(3): 351-356. Epub 2005 Nov 28. Go to original source...
  12. Galimberti V, Cole BF, Viale G. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01):10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(10): 1385-1393. Go to original source... Go to PubMed...
  13. Shah-Khan M, Boughey JC. Evolution of axillary nodal staging in brest cancer: clinical implications of the ACOSOG Z001 trial., Cancer Control.2012; 19(4): 267-276. Go to original source... Go to PubMed...
  14. Giuliano AE, Ballman KV, McCall L. Effect of axillary dissection vs no axillary dissection on 10-year overal survival among women with invasive breast cancer and sentinel node metastasis: the ACSOG Z0011, JAMA, Sep 12, 318(10): 918-926.
  15. Donker M, van Tienhoven G, Straver M. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. The Lancet Oncology,2014; 15(12): 1303-1310. Go to original source... Go to PubMed...
  16. Whelan TJOI, Olivotto I, Ackerman I. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. Journal of Clinical Oncoloy 29(18suppl): LBA1003-LBA1003, June 2011. Go to original source...
  17. Poortmans PM, Collette S, Kirkove C, et al. Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. N Engl J Med 2015; 373: 317. Go to original source...
  18. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997; 337: 949-955. Go to original source...
  19. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005; 97: 116-126. Go to original source...
  20. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106. Go to original source...
  21. Poortmans P, Struikmans H, Collette S, et al. OC-0523: Lymph node RT improves survival in breast cancer: 10 years results of the EORTC ROG and BCG phase III trial 22922/10925. Radiotherapy and Oncology. 111: S206. Go to original source...
  22. Huang CJ, Hou MF, Chuang HY, et al. Comparison of clinical outcome of breast cancer patients with T1-2 tumor and one to three positive nodes with or without postmastectomy radiation therapy.Jpn J Clin.Oncol. 2012; 42: 711-720. Go to original source... Go to PubMed...
  23. McGuire SE, Gonzalez-Angulo AM, Huang EH, Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy, Int J Radiat Oncol Biol Phys. 2007; 68(4): 1004-1009. Go to original source...
  24. Garg AK, Oh JL, Oswald MJ, et al. Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. International Journal of Radiation Oncology Biology Physics, 2007; 69(5): 1478-1483. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.